Skip to Main Content

Contribute Try STAT+ Today

pharmaceutical industry

Most Read

Stock exchange

Biotech By Adam Feuerstein, Meg Tirrell and Damian Garde

Biotech stocks are a dumpster fire. An analyst explains what’s going on

First Opinion By Yonatan Adiri

Antigen testing has some serious problems. Done right, it could reshape the future of health care

grief hardship clinicians

First Opinion By Krista Lyn Harrison, Meridith Greene and Anthony Galanos

We all need help working through grief and hardship

Hal Barron

Biotech By Matthew Herper

Did veteran drug developer Hal Barron accomplish his mission at GSK?

Health Tech By Casey Ross

‘We must change’: Health systems invest more aggressively than ever in digital health

Clinical Trials illo

Pharma By Matthew Herper

They built a smarter approach to Covid clinical trials. Now they want to do the same for other diseases

Diphtheria Vaccine

First Opinion By Christopher Hartnick

Using force crossed my mind when examining a defiant young patient. A short story made me take a breath

Watson on laptop

Health Tech By Casey Ross

The sale of Watson Health assets ends a dark chapter for IBM. For its buyer, the opportunity looks brighter

All Coverage

Trump and pharma

Politics By Dylan Scott

The drug industry’s stake in Trumpcare is bigger than you think

Heather Bresch, Doug Throckmorton Mylan

Business By Associated Press

Drug prices don’t budge even after pressure from Congress

advertisement

Pharma needs new Prescription

First Opinion By Dana P. Goldman and Darius Lakdawalla

Election verdict: Pharma needs a new prescription

Donald Trump

Politics By Dylan Scott

Big Pharma’s big question: Is Trump friend or foe?

Voting California

Politics By Rebecca Robbins

Prop 61: Californians appear to say no to lowering drug costs

Proposition 61

Politics By Rebecca Robbins and Meghana Keshavan

Drug pricing fight in California turns nasty with ads tarring pharma execs as criminals

Proposition 61 - pharmalot

The Pharmalot View By Ed Silverman

Californians can sock it to ‘greedy’ pharma. But will ballot vote bring down drug prices?

Richard Burr

Politics By Sheila Kaplan

In a tight race, one of pharma’s favorite senators gets a little help from his friends

antimicrobial resistance

First Opinion By Henry A. Waxman and Bill Corr

Waste from pharmaceutical plants in India and China promotes antibiotic-resistant superbugs

Aloquin

Pharmalot By Ed Silverman

The curious case of the $9,500 skin gel

Heather Bresch

Business By Damian Garde

The EpiPen was her ‘baby.’ Now this pharma CEO is in the hot seat over price hikes

Donald Trump sign

Politics By Dylan Scott

Donald Trump’s trade talk is making the drug industry uneasy

Dollars

Politics By Sheila Kaplan

5 ways drug makers and the health care industry are shaping campaigns

Brazil Zika microcephaly

In the Lab By Helen Branswell

The race for a Zika vaccine is intense. But it may be missing the most important players

CEO Biotech trading

Don't Miss By Damian Garde

How biotech executives profit from legal insider trades

David Vetter Bubble Boy 1977

Biotech By Damian Garde

There’s a possible cure for ‘bubble boy’ disease. It will cost $665,000

Pharmacy Benefit Managers

The Pharmalot View By Ed Silverman

The ‘gouge factor’: Big companies want transparency in drug price negotiations

Pfizer Ad

Business By Rebecca Robbins

Why Democratic convention viewers saw so many drug ads

Trump

First Opinion By Charles D. Rosen

Say what you will about Donald Trump. He’s right about drug companies

Mark Cuban

Don't Miss By Dylan Scott

Billionaire businessman Mark Cuban has something to say about drug prices

Acetylcholine receptor

Biotech By Damian Garde

Could a molecular ‘on-off switch for agony’ lead to a safer painkiller?

Hospitals Corridor

Business By Charles Ornstein and Ryann Grochowski Jones — ProPublica

Drug and device makers find receptive audience at for-profit, Southern hospitals

Drug Industry Overstates Patents

The Pharmalot View By Ed Silverman

Drug industry overstates impact of patent reviews on innovation

Brexit

Biotech By Meghana Keshavan and Rebecca Robbins

Post-Brexit, will the European Medicines Agency be homeless?

Supreme Court

Politics By Dylan Scott

Supreme Court’s ruling in patent case a blow to drug industry